BeiGene, Ltd. 1,511,546 American Depositary Shares Representing 19,650,098 Ordinary Shares (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • December 2nd, 2020 • BeiGene, Ltd. • Pharmaceutical preparations • New York
The ADSs purchased by the Underwriters will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to a deposit agreement (the “Deposit Agreement”), dated as of February 5, 2016 and as amended on April 11, 2016, among the Company, Citibank, N.A., as depositary (the “Depositary”), and holders from time to time of the ADRs. Each ADS represents the right to receive 13 Ordinary Shares deposited pursuant to the Deposit Agreement.
AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 2nd, 2020 • BeiGene, Ltd. • Pharmaceutical preparations • New York
This Amendment No. 1 to the Registration Rights Agreement (this “Amendment”) is made as of December 1, 2020 and effective as of December 31, 2020, by and among BeiGene, Ltd., a Cayman Islands exempted company (the “Company”) and the undersigned Investors. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Registration Rights Agreement dated as of November 16, 2016, by and among the Company and the Investors thereto (the “Registration Rights Agreement”).
